Alpha 2.0
Login Register
» Journals » J Comp Eff Res

Journal of Comparative Effectiveness Research

Journal of Comparative Effectiveness Research is a scientific journal, published since 2012 in English. The journal's country of origin is United Kingdom and its primary focus area is health services.
Details
Abbr. J Comp Eff Res
Start 2012
End Continuing
Frequency Sixteen no. a year, 2019-
p-ISSN 2042-6305
e-ISSN 2042-6313
Country United Kingdom
Language English
Specialty Health Services
Metrics
h-index / Ranks: 9739 34
SJR / Ranks: 7794 579
CiteScore / Ranks: 8368 3.10
JIF / Ranks: 5004 2.1
Recent Articles
1.
Real-world evidence: state-of-the-art and future perspectives
Fitzke H, Fayzan T, Watkins J, Galimov E, Pierce B
J Comp Eff Res . 2025 Mar; :e240130. PMID: 40051332
Recent developments in digital infrastructure, advanced analytical approaches, and regulatory settings have facilitated the broadened use of real-world evidence (RWE) in population health management and evaluation of novel health technologies....
2.
Burden of illness for patients with primary biliary cholangitis: an observational study of clinical characteristics and healthcare resource utilization
Gish R, MacEwan J, Levine A, Lebovitch D, Bessonova L, Wheeler D, et al.
J Comp Eff Res . 2025 Mar; :e240174. PMID: 40047576
To evaluate the clinical characteristics and healthcare resource utilization for acute care and its costs for patients with primary biliary cholangitis (PBC) with or without cirrhosis. This retrospective observational cohort...
3.
Mapping methods gaps between EU joint clinical assessments and local health technology assessment decision-making: an environmental scan of guidance in select EU markets and harmonization challenges
Sarri G, Vinals L, Leisle L, Chau I, Smalbrugge D, Lucassen K, et al.
J Comp Eff Res . 2025 Feb; :e240240. PMID: 40008768
Under the newly instituted health technology assessment (HTA) regulation (HTAR), health technology developers must build evidence packages that meet the needs for both the upcoming EU joint clinical assessment (JCA)...
4.
Evaluation of reporting in time-driven activity-based costing studies on cardiovascular diseases: a scoping review
Schneider N, Roos E, Zago Marcolino M, Caldana F, Vargas do Nascimento F, da Rosa Decker S, et al.
J Comp Eff Res . 2025 Feb; :e240013. PMID: 40008693
This scoping review evaluates the application of the time-driven activity-based costing (TDABC) methodology in cardiovascular disease (CVD) studies. The evaluation was conducted using the 32-item TDABC Healthcare Consortium Consensus Statement...
5.
Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitis
Jairath V, Raine T, Leahy T, Potluri R, Wosik K, Gruben D, et al.
J Comp Eff Res . 2025 Feb; :e240193. PMID: 39989343
Etrasimod and ozanimod are selective sphingosine 1-phosphate receptor modulators targeting the S1P, and S1P receptors, respectively, for the treatment of patients with moderately to severely active ulcerative colitis (UC). No...
6.
Comparison of real-world healthcare resource utilization and costs among patients with hereditary angioedema on lanadelumab or berotralstat long-term prophylaxis
Princic N, Evans K, Shah C, Sing K, Juethner S, Schultz B
J Comp Eff Res . 2025 Feb; :e240205. PMID: 39976166
Hereditary angioedema (HAE) is a rare and chronic genetic condition. Lanadelumab and berotralstat, two plasma kallikrein inhibitors, have both been approved for long-term prophylaxis in patients with HAE; however, real-world...
7.
The role of health economic evidence in clinical practice guidelines for colorectal cancer: a comparative analysis across countries
Yan X, Wang Y, Ma A, Li H
J Comp Eff Res . 2025 Feb; :e240226. PMID: 39969114
Colorectal cancer (CRC) is among the most prevalent malignancies globally and causes massive resource consumption and economic burden. Health economic evidence (HEE) has been used in clinical practice guidelines (CPGs)...
8.
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 18
Arora P, Ramagopalan S
J Comp Eff Res . 2025 Feb; :e250014. PMID: 39963965
In this update, we discuss recent publications examining the use of real-world data as a measure of treatment effectiveness in submissions to the National Institute of Health and Care Excellence,...
9.
The economic impact of stent retriever selection for acute ischemic stroke: a cost analysis of MASTRO I from the healthcare system perspective of the United States, Canada and eight European countries
Andersson T, Nordmeyer H, Brinjikji W, Kottenmeier E, Kabiri M, Scheffler S, et al.
J Comp Eff Res . 2025 Feb; 14(3):e240216. PMID: 39957470
According to the results of the MASTRO I living systematic review and meta-analysis, use of the EmboTrap Revascularization Device in the treatment of acute ischemic stroke (AIS) results in higher...
10.
Clinical characteristics and treatment outcomes in multiple sclerosis patients treated with anti-CD20s who switched to fumarates: a retrospective analysis of a US healthcare claims database
Ben-Zacharia A, Feng J, Moss B, Belviso N, Zhang Y, Branco F, et al.
J Comp Eff Res . 2025 Feb; 14(3):e240071. PMID: 39936542
Anti-CD20 monoclonal antibodies and fumarates are common multiple sclerosis (MS) disease-modifying therapies (DMTs). Data on switching from anti-CD20s to other DMTs are limited. This retrospective, observational study of the US...